- Home
- SENEA vs TRVI Comparison
SENEA vs TRVI Comparison
Compare SENEA & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEA
- TRVI
- Stock Information
- Founded
- SENEA 1949
- TRVI 2011
- Country
- SENEA United States
- TRVI United States
- Employees
- SENEA N/A
- TRVI N/A
- Industry
- SENEA Packaged Foods
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- SENEA Consumer Staples
- TRVI Health Care
- Exchange
- SENEA Nasdaq
- TRVI Nasdaq
- Market Cap
- SENEA 629.3M
- TRVI 629.8M
- IPO Year
- SENEA N/A
- TRVI 2019
- Fundamental
- Price
- SENEA $94.31
- TRVI $6.42
- Analyst Decision
- SENEA
- TRVI Strong Buy
- Analyst Count
- SENEA 0
- TRVI 8
- Target Price
- SENEA N/A
- TRVI $19.31
- AVG Volume (30 Days)
- SENEA 16.4K
- TRVI 1.0M
- Earning Date
- SENEA 06-12-2025
- TRVI 05-08-2025
- Dividend Yield
- SENEA N/A
- TRVI N/A
- EPS Growth
- SENEA 25.61
- TRVI N/A
- EPS
- SENEA 5.45
- TRVI N/A
- Revenue
- SENEA $1,541,031,000.00
- TRVI N/A
- Revenue This Year
- SENEA N/A
- TRVI N/A
- Revenue Next Year
- SENEA N/A
- TRVI N/A
- P/E Ratio
- SENEA $17.31
- TRVI N/A
- Revenue Growth
- SENEA 4.00
- TRVI N/A
- 52 Week Low
- SENEA $51.79
- TRVI $2.30
- 52 Week High
- SENEA $94.86
- TRVI $7.39
- Technical
- Relative Strength Index (RSI)
- SENEA 62.77
- TRVI 56.14
- Support Level
- SENEA $89.47
- TRVI $6.08
- Resistance Level
- SENEA $94.11
- TRVI $6.47
- Average True Range (ATR)
- SENEA 2.25
- TRVI 0.39
- MACD
- SENEA 0.26
- TRVI -0.00
- Stochastic Oscillator
- SENEA 100.00
- TRVI 45.06
About SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.